Emerging Immunotherapy for Acute Myeloid Leukemia.
Animals
Antibodies, Bispecific
/ therapeutic use
Clinical Trials as Topic
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immune Checkpoint Proteins
/ metabolism
Immunoconjugates
/ therapeutic use
Immunologic Factors
/ therapeutic use
Immunotherapy, Adoptive
/ methods
Leukemia, Myeloid, Acute
/ metabolism
Receptors, Chimeric Antigen
/ therapeutic use
Survival Rate
acute myeloid leukemia (AML)
bispecific T-cell engager (BiTE)
chimeric antigen receptor (CAR)
dual-affinity retargeting (DART)
immune check-point inhibitor (ICI)
trispecific killer cell engager (TriKE)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
received:
23
01
2021
revised:
11
02
2021
accepted:
12
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
27
4
2021
Statut:
epublish
Résumé
Several immune checkpoint molecules and immune targets in leukemic cells have been investigated. Recent studies have suggested the potential clinical benefits of immuno-oncology (IO) therapy against acute myeloid leukemia (AML), especially targeting CD33, CD123, and CLL-1, as well as immune checkpoint inhibitors (e.g., anti-PD (programmed cell death)-1 and anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) antibodies) with or without conventional chemotherapy. Early-phase clinical trials of chimeric antigen receptor (CAR)-T or natural killer (NK) cells for relapsed/refractory AML showed complete remission (CR) or marked reduction of marrow blasts in a few enrolled patients. Bi-/tri-specific antibodies (e.g., bispecific T-cell engager (BiTE) and dual-affinity retargeting (DART)) exhibited 11-67% CR rates with 13-78% risk of cytokine-releasing syndrome (CRS). Conventional chemotherapy in combination with anti-PD-1/anti-CTLA4 antibody for relapsed/refractory AML showed 10-36% CR rates with 7-24 month-long median survival. The current advantages of IO therapy in the field of AML are summarized herein. However, although cancer vaccination should be included in the concept of IO therapy, it is not mentioned in this review because of the paucity of relevant evidence.
Identifiants
pubmed: 33669431
pii: ijms22041944
doi: 10.3390/ijms22041944
pmc: PMC7920435
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Immune Checkpoint Inhibitors
0
Immune Checkpoint Proteins
0
Immunoconjugates
0
Immunologic Factors
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
Haematologica. 2010 Jan;95(1):71-8
pubmed: 19648166
J Clin Oncol. 2008 Nov 10;26(32):5192-7
pubmed: 18854573
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35017151
Haematologica. 2011 Dec;96(12):1792-8
pubmed: 21933861
Cureus. 2019 Feb 20;11(2):e4103
pubmed: 31057997
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Nature. 2015 Jan 15;517(7534):386-90
pubmed: 25363763
Clin Cancer Res. 2017 Feb 15;23(4):1068-1079
pubmed: 27856600
Blood Cancer J. 2017 Jun 2;7(6):e567
pubmed: 28574487
Blood. 2011 Apr 28;117(17):4501-10
pubmed: 21385853
J Hematol Oncol. 2015 Jul 30;8:93
pubmed: 26219463
J Immunol. 2008 Jun 1;180(11):7358-67
pubmed: 18490735
Blood. 2007 Oct 1;110(7):2659-66
pubmed: 17609428
Mol Ther. 2013 Nov;21(11):2122-9
pubmed: 23831595
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Nat Rev Cancer. 2003 Sep;3(9):650-65
pubmed: 12951584
Eur J Immunol. 1994 Dec;24(12):3216-21
pubmed: 7805750
Blood. 2016 Apr 28;127(17):2157-60
pubmed: 26929274
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6880-8
pubmed: 25400771
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567
Blood. 2002 Mar 15;99(6):2146-53
pubmed: 11877291
Gene. 2018 Jan 5;638:20-25
pubmed: 28951311
Transfusion. 2019 Jul;59(7):2248-2254
pubmed: 31183877
Blood. 2018 Apr 5;131(14):1617-1621
pubmed: 29439955
Blood. 2017 Feb 2;129(5):609-618
pubmed: 27908880
Blood Cancer J. 2014 Jun 13;4:e218
pubmed: 24927407
J Immunol. 2009 Feb 15;182(4):1885-91
pubmed: 19201841
Eur J Immunol. 1996 May;26(5):1180-6
pubmed: 8647185
Br J Haematol. 2018 Apr;181(1):38-53
pubmed: 29318591
Blood. 2012 Mar 29;119(13):3064-72
pubmed: 22323453
Blood Cancer J. 2015 Jul 31;5:e330
pubmed: 26230954
J Immunol. 2005 Nov 15;175(10):6420-7
pubmed: 16272294
Haematologica. 2011 Oct;96(10):1548-51
pubmed: 21791474
Clin Cancer Res. 2017 Jul 1;23(13):3385-3395
pubmed: 28096272
Blood. 2009 Feb 12;113(7):1581-8
pubmed: 18974373
Expert Rev Anticancer Ther. 2016 Aug;16(8):811-26
pubmed: 27403706
J Immunol. 2010 Jun 1;184(11):6545-51
pubmed: 20421648
Eur J Immunol. 2013 Oct;43(10):2741-9
pubmed: 23817958
Immunity. 2000 Aug;13(2):233-42
pubmed: 10981966
PLoS One. 2015 Oct 22;10(10):e0140694
pubmed: 26492563
Blood. 2018 Dec 6;132(23):2484-2494
pubmed: 30275109
Mol Ther. 2011 Sep;19(9):1727-36
pubmed: 21587210
Leukemia. 2014 Jun;28(6):1280-8
pubmed: 24270737
Cell Immunol. 2007 Nov-Dec;250(1-2):68-74
pubmed: 18353298
Ann N Y Acad Sci. 2011 Jan;1217:45-59
pubmed: 21276005
Leukemia. 2018 May;32(5):1168-1179
pubmed: 29472720
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10650-5
pubmed: 21670307
Cancer. 2019 May 1;125(9):1470-1481
pubmed: 30500073
J Exp Med. 2011 Feb 14;208(2):395-407
pubmed: 21300912
J Immunol. 2001 Sep 1;167(5):2547-54
pubmed: 11509594
Blood. 2016 Mar 17;127(11):1410-6
pubmed: 26755709
Leukemia. 2017 Mar;31(3):738-743
pubmed: 27840427
Clin Cancer Res. 2015 Sep 1;21(17):3977-85
pubmed: 25957287
J Hematol Oncol. 2019 Apr 24;12(1):41
pubmed: 31014360
Ann Rheum Dis. 2016 Jul;75(7):1386-91
pubmed: 26275430
Chin J Cancer Res. 2017 Oct;29(5):463-470
pubmed: 29142466
Leukemia. 2019 Apr;33(4):931-944
pubmed: 30291336
Clin Cancer Res. 2018 Aug 1;24(15):3519-3527
pubmed: 29716921
Leukemia. 2014 Aug;28(8):1596-605
pubmed: 24504024
Mol Ther. 2015 Jan;23(1):184-91
pubmed: 25174587
Blood. 2012 Apr 19;119(16):3705-11
pubmed: 22378848
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Front Immunol. 2013 Dec 10;4:449
pubmed: 24339828
Lancet Haematol. 2019 Sep;6(9):e480-e488
pubmed: 31400961
J Hematol Oncol. 2015 Apr 16;8:36
pubmed: 25886742
Eur J Immunol. 2014 Sep;44(9):2703-2711
pubmed: 24838857
Blood Adv. 2018 Jul 24;2(14):1738-1749
pubmed: 30037800
J Hematol Oncol. 2018 Jan 10;11(1):7
pubmed: 29316944
Blood. 2016 Jan 7;127(1):122-31
pubmed: 26531164
Haematologica. 2001 Dec;86(12):1261-9
pubmed: 11726317
Blood. 2018 Jan 4;131(1):30-38
pubmed: 29118005
Biomark Res. 2014 Feb 10;2(1):4
pubmed: 24513123
Lancet Oncol. 2019 Jul;20(7):984-997
pubmed: 31175001
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Nat Immunol. 2012 Sep;13(9):832-42
pubmed: 22842346
Leukemia. 2017 May;31(5):1059-1068
pubmed: 27795558
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
J Virol. 2013 May;87(9):4835-45
pubmed: 23408620
J Immunol. 2010 Feb 15;184(4):1918-30
pubmed: 20083673
J Exp Med. 2001 Apr 2;193(7):855-62
pubmed: 11283158
Blood Adv. 2018 Apr 24;2(8):848-858
pubmed: 29661755
Immunity. 2014 Mar 20;40(3):389-99
pubmed: 24631154
J Immunol. 2016 Oct 1;197(7):2715-25
pubmed: 27566820
J Clin Oncol. 2016 Mar 20;34(9):972-9
pubmed: 26811524
Leuk Res. 2017 May;56:1-6
pubmed: 28152413
Annu Rev Immunol. 2006;24:65-97
pubmed: 16551244
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
Mol Ther. 2016 Sep 29;24(9):1615-26
pubmed: 27401038
Clin Cancer Res. 2021 Jun 1;27(11):3141-3153
pubmed: 33531429
Clin Cancer Res. 2019 Feb 15;25(4):1358-1368
pubmed: 29959143
J Exp Med. 1991 Sep 1;174(3):561-9
pubmed: 1714933
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
Blood. 2005 Mar 15;105(6):2421-7
pubmed: 15383453
Leukemia. 2011 May;25(5):792-9
pubmed: 21274000
PLoS One. 2015 Apr 10;10(4):e0124241
pubmed: 25860287
J Clin Oncol. 2016 Apr 1;34(10):1104-11
pubmed: 26884582
Am J Cancer Res. 2018 Sep 01;8(9):1899
pubmed: 30323981
Mol Cancer Ther. 2014 Jun;13(6):1549-57
pubmed: 24674885
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Blood. 2005 Dec 15;106(13):4086-92
pubmed: 16131573
Leukemia. 2020 Oct;34(10):2688-2703
pubmed: 32358567
N Engl J Med. 2016 Jul 14;375(2):143-53
pubmed: 27410923
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Int J Mol Sci. 2017 Oct 27;18(11):
pubmed: 29077054
Cell. 2009 Jul 23;138(2):271-85
pubmed: 19632178
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
Nat Immunol. 2003 Nov;4(11):1093-101
pubmed: 14556005
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Angew Chem Int Ed Engl. 2014 Sep 8;53(37):9841-5
pubmed: 25056598
Blood. 2020 Mar 5;135(10):713-723
pubmed: 31951650
Cancer Biol Ther. 2008 May;7(5):622-7
pubmed: 18756622
J Immunol. 2004 Aug 15;173(4):2500-6
pubmed: 15294965
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861
Mol Ther. 2017 Sep 6;25(9):2202-2213
pubmed: 28676343